## Top 10 drugs 2017-18

Aust Prescr 2018;41:194 https://doi.org/10.18773/ austprescr.2018.067 Tables 1–3 show the top 10 drugs for the year July 2017 – June 2018. The figures are based on PBS and RPBS prescriptions from the date of supply. The figures include prescriptions under the co-payment (non-subsidised).

Table 1 Top 10 drugs by DDD/1000 pop/day

| Drug |              | DDD/1000 pop/day* |  |
|------|--------------|-------------------|--|
| 1.   | atorvastatin | 71.34             |  |
| 2.   | rosuvastatin | 54.02             |  |
| 3.   | perindopril  | 51.55             |  |
| 4.   | amlodipine   | 46.84             |  |
| 5.   | irbesartan   | 33.29             |  |
| 6.   | candesartan  | 33.11             |  |
| 7.   | telmisartan  | 30.89             |  |
| 8.   | esomeprazole | 29.40             |  |
| 9.   | ramipril     | 27.93             |  |
| 10.  | metformin    | 24.89             |  |

None of the most frequently prescribed drugs in Australia appears in the Top 10 drugs by cost. That list is dominated by sofosbuvir and its combinations for the treatment of hepatitis C.

Table 2 Top 10 drugs by prescription counts

| Dru | g                             | Prescriptions |  |
|-----|-------------------------------|---------------|--|
| 1.  | rosuvastatin                  | 11 246 365    |  |
| 2.  | atorvastatin                  | 10 863 219    |  |
| 3.  | esomeprazole                  | 9 442 144     |  |
| 4.  | pantoprazole                  | 7 112 063     |  |
| 5.  | perindopril                   | 6 466 954     |  |
| 6.  | cefalexin                     | 5 458 659     |  |
| 7.  | amoxicillin                   | 5 253 018     |  |
| 8.  | metformin                     | 5 006 664     |  |
| 9.  | amoxicillin + clavulanic acid | 4 680 931     |  |
| 10. | escitalopram                  | 4 187 180     |  |

Table 3 Top 10 drugs by cost to government (does not include rebates)

| Drug |                          | Cost to government | DDD/1000 pop/day* | Prescriptions |
|------|--------------------------|--------------------|-------------------|---------------|
| 1.   | sofosbuvir + velpatasvir | \$695 729 924      | †                 | 31 079        |
| 2.   | aflibercept              | \$324 696 598      | †                 | 255 264       |
| 3.   | adalimumab               | \$322 733 592      | 41.48             | 229 719       |
| 4.   | ledipasvir + sofosbuvir  | \$244 917 648      | †                 | 10 990        |
| 5.   | ranibizumab              | \$218 702 078      | †                 | 174 627       |
| 6.   | nivolumab                | \$215 410 197      | †                 | 43 215        |
| 7.   | sofosbuvir               | \$204 520 430      | 0.99              | 10 451        |
| 8.   | denosumab                | \$189 073 508      | 44.26             | 673 160       |
| 9.   | trastuzumab              | \$169 958 330      | †                 | 55 980        |
| 10.  | pembrolizumab            | \$148 956 436      | †                 | 17 631        |

DDD defined daily dose

PBS Pharmaceutical Benefits Scheme

RPBS Repatriation Pharmaceutical Benefits Scheme

- \* DDD/thousand population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. DDD includes use in combination products. The calculation is based on ABS 3101.0 Australian Demographic Statistics for December 2017 (as at March 2018).
- <sup>†</sup> The World Health Organization has not allocated a DDD for this drug.

Source: Department of Health, October 2018. ©Commonwealth of Australia